Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Receivables (2021 - 2023)

SAB Biotherapeutics' Change in Receivables history spans 3 years, with the latest figure at -$361735.0 for Q3 2023.

  • For Q3 2023, Change in Receivables fell 110.86% year-over-year to -$361735.0; the TTM value through Dec 2023 reached -$5.6 million, down 126.42%, while the annual FY2023 figure was -$5.6 million, 126.42% down from the prior year.
  • Change in Receivables reached -$361735.0 in Q3 2023 per SABSW's latest filing, up from -$401388.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $5.5 million in Q2 2021 to a low of -$9.0 million in Q1 2021.
  • Average Change in Receivables over 3 years is -$1.9 million, with a median of -$2.2 million recorded in 2022.
  • The largest YoY upside for Change in Receivables was 148.28% in 2022 against a maximum downside of 235.32% in 2022.
  • A 3-year view of Change in Receivables shows it stood at -$2.2 million in 2021, then tumbled by 235.32% to -$7.4 million in 2022, then skyrocketed by 95.1% to -$361735.0 in 2023.
  • Per Business Quant, the three most recent readings for SABSW's Change in Receivables are -$361735.0 (Q3 2023), -$401388.0 (Q2 2023), and -$4.8 million (Q1 2023).